D. Medical taps ROW for growth; visibility with NASDAQ listing

As Canadian companies are increasingly looking south to raise the capital they need to fund their growth, biotuesdays.com decided to take a close look at one of the most recent foreign healthcare company IPO’s on NASDAQ.  D. Medical Industries (NASDAQ: DMED; TASE: DMDC) completed its U.S. IPO in early August.  This has given the medical [...]

Pharmachem wins battle for Forbes Medi-Tech

The bidding battle for the assets of Forbes Medi-Tech (OTCBB:FMTI) appears to have concluded with the company declaring Pharmachem Laboratories the winner. Forbes said MHT LLC has declined to match an offer made by Pharmachem to acquire substantially all of the assets of Forbes for $4 million (U.S.) and the board is recommending that shareholders [...]

Bioniche-Endo set for additional Phase 3 trial

Bioniche Life Sciences (TSX:BNC) and its development partner, Endo Pharmaceuticals (NASDAQ: ENDP), are in the process of finalizing a protocol for an additional Phase 3 clinical trial of their Urocidin bladder cancer drug, which is expected to begin enrolling patients in 2010. “We’re preparing to initiate a large study with Urocidin in the second half [...]

Interinvest holds 10% of Amorfix

Interinvest Group of Companies of Boston has acquired direction or control through open market purchases of a total of 4,862,550 common shares of Amorfix Life Sciences (TSX:AMF), or 10% of the outstanding common shares, for investment purposes. Interinvest chairman Dr. Hans Black is also a director of Amorfix. Both he and Michael Sonnenreich, also a [...]

In conversation with Thomas Wellner

As CEO of closely held Therapure Biopharma, Thomas Wellner is lifting the contract development and manufacturing organization (CDMO) out of the ashes of Hemosol, which fell into receivership in 2005 and was acquired in 2007 by privately owned Catalyst Fund Limited Partnership, a private equity fund in Toronto.  With a global focus on business development [...]

Cangene to target North America for products

Cangene (TSX:CNJ) plans to focus its commercialization efforts in North America in the near-term and intends to withdraw a European marketing license for a single indication of human hepatitis B immunoglobulin. The company said it has decided that the “size of the European market for this indication alone does not currently warrant further commercialization efforts.” [...]

MDS extends cobalt-60 pact with OPG

MDS’ (TSX:MDS) Nordion unit has extended its existing agreement with Ontario Power Generation until 2020 for the supply of cobalt-60 used in gamma sterilization technologies for its global customer base making medical sterilization and sealed source products. “Executing on this agreement … enables MDS Nordion to continue building on its strong market position in the [...]

Medicago offers $7 million of units

Medicago (TSX:MDG) has entered into an agency agreement and carried out an overnight marketed offering to sell up to 17,283,952 units at a price of 40.5 cents each in order to finance its $7.5 million share of a new U.S. pandemic vaccine plant that includes a grant from an arm of the U.S. Department of [...]

Angelini Labopharm joint venture launches Oleptro

Labopharm (TSX:DDS; NASDAQ:DDSS) and its joint venture partner Gruppo Angelini have launched Oleptro, an once-daily formulation of the antidepressant trazodone, in the U.S. “The commercialization strategy for Oleptro is based on extensive research into the physician, patient and payer audiences and employs a targeted, efficient sales effort that is designed to maximize the return on [...]

YM gets orphan drug status for JAK1/2 drug

The FDA has granted orphan drug status to YM BioSciences’ (TSX:YM; AMEX:YMI) JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, in which a patient’s bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory. The designation provides YM with seven years of U.S. marketing exclusivity, tax credits for clinical [...]

« Previous Page — Next Page »